help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snyder, P. J.
Right arrow Articles by Strom, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snyder, P. J.
Right arrow Articles by Strom, B. L.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 8 2670-2677
Copyright © 2000 by The Endocrine Society

From the Clinical Research Centers

Effects of Testosterone Replacement in Hypogonadal Men1

Peter J. Snyder, Helen Peachey, Jesse A. Berlin, Peter Hannoush, Ghada Haddad, Abdallah Dlewati, Jill Santanna, Louise Loh, David A. Lenrow, John H. Holmes, Shiv C. Kapoor, Linda E. Atkinson and Brian L. Strom

Departments of Medicine (P.J.S., H.P., P.H., G.H., A.D., L.L., S.K., B.L.S.), Biostatistics and Epidemiology (J.B., J.S., J.H.H., B.L.S.), and Rehabilitation Medicine (D.A.L.), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104; and Alza Corp. (L.E.A.), Mountain View, California 00000

Address all correspondence and requests for reprints to: Dr. Peter J. Snyder, 615 Curie Boulevard, Philadelphia, Pennsylvania 19104.

Treatment of hypogonadal men with testosterone has been shown to ameliorate the effects of testosterone deficiency on bone, muscle, erythropoiesis, and the prostate. Most previous studies, however, have employed somewhat pharmacological doses of testosterone esters, which could result in exaggerated effects, and/or have been of relatively short duration or employed previously treated men, which could result in dampened effects. The goal of this study was to determine the magnitude and time course of the effects of physiological testosterone replacement for 3 yr on bone density, muscle mass and strength, erythropoiesis, prostate volume, energy, sexual function, and lipids in previously untreated hypogonadal men.

We selected 18 men who were hypogonadal (mean serum testosterone ± SD, 78 ± 77 ng/dL; 2.7 ± 2.7 nmol/L) due to organic disease and had never previously been treated for hypogonadism. We treated them with testosterone transdermally for 3 yr. Sixteen men completed 12 months of the protocol, and 14 men completed 36 months. The mean serum testosterone concentration reached the normal range by 3 months of treatment and remained there for the duration of treatment. Bone mineral density of the lumbar spine (L2–L4) increased by 7.7 ± 7.6% (P < 0.001), and that of the femoral trochanter increased by 4.0 ± 5.4% (P = 0.02); both reached maximum values by 24 months. Fat-free mass increased 3.1 kg (P = 0.004), and fat-free mass of the arms and legs individually increased, principally within the first 6 months. The decrease in fat mass was not statistically significant. Strength of knee flexion and extension did not change. Hematocrit increased dramatically, from mildly anemic (38.0 ± 3.0%) to midnormal (43.1 ± 4.0%; P = 0.002) within 3 months, and remained at that level for the duration of treatment. Prostate volume also increased dramatically, from subnormal (12.0 ± 6.0 mL) before treatment to normal (22.4 ± 8.4 mL; P = 0.004), principally during the first 6 months. Self-reported sense of energy (49 ± 19% to 66 ± 24%; P = 0.01) and sexual function (24 ± 20% to 66 ± 24%; P < 0.001) also increased, principally within the first 3 months. Lipids did not change.

We conclude from this study that replacing testosterone in hypogonadal men increases bone mineral density of the spine and hip, fat-free mass, prostate volume, erythropoiesis, energy, and sexual function. The full effect of testosterone on bone mineral density took 24 months, but the full effects on the other tissues took only 3–6 months. These results provide the basis for monitoring the magnitude and the time course of the effects of testosterone replacement in hypogonadal men.




This article has been cited by other articles:


Home page
 J AndrolHome page
A. A. Yassin and F. Saad
Testosterone and Erectile Dysfunction
J Androl, November 1, 2008; 29(6): 593 - 604.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
B. C. Clark and T. M. Manini
Sarcopenia != Dynapenia
J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2008; 63(8): 829 - 834.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. T. Page, J. K. Amory, and W. J. Bremner
Advances in Male Contraception
Endocr. Rev., June 1, 2008; 29(4): 465 - 493.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Fukui, M. Tanaka, G. Hasegawa, T. Yoshikawa, and N. Nakamura
Association Between Serum Bioavailable Testosterone Concentration and the Ratio of Glycated Albumin to Glycated Hemoglobin in Men With Type 2 Diabetes
Diabetes Care, March 1, 2008; 31(3): 397 - 401.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
S. T. Page, W. J. Bremner, R. V. Clark, M. A. Bush, H. Zhi, R. B. Caricofe, P. M. Smith, and J. K. Amory
Nanomilled Oral Testosterone Plus Dutasteride Effectively Normalizes Serum Testosterone in Normal Men With Induced Hypogonadism
J Androl, March 1, 2008; 29(2): 222 - 227.
[Abstract] [Full Text] [PDF]

Home page
 J Bone Joint Surg BrHome page
S. Sharma, M. Fraser, F. Lovell, A. Reece, and A. R. McLellan
Characteristics of males over 50 years who present with a fracture: EPIDEMIOLOGY AND UNDERLYING RISK FACTORS
J Bone Joint Surg Br, January 1, 2008; 90-B(1): 72 - 77.
[Abstract] [Full Text] [PDF]

Home page
 cfpHome page
A. Katz, A. Katz, and C. Burchill
Androgen therapy: Testing before prescribing and monitoring during therapy
Can Fam Physician, November 1, 2007; 53(11): 1936 - 1942.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. P. Liu and M. Fukuoka
Sex Hormones as Novel Risk Biomarkers for Atherosclerosis in Peripheral Vascular Disease
J. Am. Coll. Cardiol., September 11, 2007; 50(11): 1077 - 1079.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. M. Greenfield, S. J. Walters, R. E. Coleman, B. W. Hancock, R. Eastell, H. A. Davies, J. A. Snowden, L. Derogatis, S. M. Shalet, and R. J. M. Ross
Prevalence and Consequences of Androgen Deficiency in Young Male Cancer Survivors in a Controlled Cross-Sectional Study
J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3476 - 3482.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. K. Miller, B. M. K. Biller, A. Schaub, K. Pulaski-Liebert, G. Bradwin, N. Rifai, and A. Klibanski
Effects of Testosterone Therapy on Cardiovascular Risk Markers in Androgen-Deficient Women with Hypopituitarism
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2474 - 2479.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Bhasin, R. A. Parker, F. Sattler, R. Haubrich, B. Alston, T. Umbleja, C. M. Shikuma, and for the AIDS Clinical Trials Group Protocol A5079
Effects of Testosterone Supplementation on Whole Body and Regional Fat Mass and Distribution in Human Immunodeficiency Virus-Infected Men with Abdominal Obesity
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1049 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
L. S. Marks, N. A. Mazer, E. Mostaghel, D. L. Hess, F. J. Dorey, J. I. Epstein, R. W. Veltri, D. V. Makarov, A. W. Partin, D. G. Bostwick, et al.
Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism: A Randomized Controlled Trial.
JAMA, November 15, 2006; 296(19): 2351 - 2361.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A.-M. Axell, H. E. MacLean, D. R. Plant, L. J. Harcourt, J. A. Davis, M. Jimenez, D. J. Handelsman, G. S. Lynch, and J. D. Zajac
Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice
Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E506 - E516.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. Sinha-Hikim, M. Cornford, H. Gaytan, M. L. Lee, and S. Bhasin
Effects of Testosterone Supplementation on Skeletal Muscle Fiber Hypertrophy and Satellite Cells in Community-Dwelling Older Men
J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3024 - 3033.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
L. Ferrucci, M. Maggio, S. Bandinelli, S. Basaria, F. Lauretani, A. Ble, G. Valenti, W. B. Ershler, J. M. Guralnik, and D. L. Longo
Low testosterone levels and the risk of anemia in older men and women.
Arch Intern Med, July 10, 2006; 166(13): 1380 - 1388.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Bhasin, G. R. Cunningham, F. J. Hayes, A. M. Matsumoto, P. J. Snyder, R. S. Swerdloff, and V. M. Montori
Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 1995 - 2010.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
E. L. Ding, Y. Song, V. S. Malik, and S. Liu
Sex Differences of Endogenous Sex Hormones and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis
JAMA, March 15, 2006; 295(11): 1288 - 1299.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
V Rochira, A Balestrieri, B Madeo, L Zirilli, A R M Granata, and C Carani
Osteoporosis and male age-related hypogonadism: role of sex steroids on bone (patho)physiology
Eur. J. Endocrinol., February 1, 2006; 154(2): 175 - 185.
[Abstract] [Full Text] [PDF]

Home page
 Nutr Clin PractHome page
D. R. Thomas
Guidelines for the Use of Orexigenic Drugs in Long-Term Care
Nutr Clin Pract, February 1, 2006; 21(1): 82 - 87.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. G. Giannoulis, P. H. Sonksen, M. Umpleby, L. Breen, C. Pentecost, M. Whyte, C. V. McMillan, C. Bradley, and F. C. Martin
The Effects of Growth Hormone and/or Testosterone in Healthy Elderly Men: A Randomized Controlled Trial
J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 477 - 484.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
J. K. Amory, S. T. Page, and W. J. Bremner
Oral Testosterone in Oil: Pharmacokinetic Effects of 5{alpha} Reduction by Finasteride or Dutasteride and Food Intake in Men
J Androl, January 1, 2006; 27(1): 72 - 78.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Singh, J. N. Artaza, W. E. Taylor, M. Braga, X. Yuan, N. F. Gonzalez-Cadavid, and S. Bhasin
Testosterone Inhibits Adipogenic Differentiation in 3T3-L1 Cells: Nuclear Translocation of Androgen Receptor Complex with {beta}-Catenin and T-Cell Factor 4 May Bypass Canonical Wnt Signaling to Down-Regulate Adipogenic Transcription Factors
Endocrinology, January 1, 2006; 147(1): 141 - 154.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
E. T. Schroeder, A. F. Vallejo, L. Zheng, Y. Stewart, C. Flores, S. Nakao, C. Martinez, and F. R. Sattler
Six-Week Improvements in Muscle Mass and Strength During Androgen Therapy in Older Men
J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2005; 60(12): 1586 - 1592.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. Laghi
Low Testosterone in Chronic Obstructive Pulmonary Disease: Does It Really Matter?
Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1069 - 1070.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
W. Gao, P. J. Reiser, C. C. Coss, M. A. Phelps, J. D. Kearbey, D. D. Miller, and J. T. Dalton
Selective Androgen Receptor Modulator Treatment Improves Muscle Strength and Body Composition and Prevents Bone Loss in Orchidectomized Rats
Endocrinology, November 1, 2005; 146(11): 4887 - 4897.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. M. Kaufman and A. Vermeulen
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Endocr. Rev., October 1, 2005; 26(6): 833 - 876.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Shafqat, L. H. Einhorn, N. Hanna, G. W. Sledge, A. Hanna, B. E. Juliar, P. Monahan, and S. Bhatia
Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment{dagger}
Ann. Onc., September 1, 2005; 16(9): 1545 - 1550.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
G. G T'Sjoen, Y. Beguin, E. Feyen, R. Rubens, J.-M. Kaufman, and L. Gooren
Influence of exogenous oestrogen or (anti-) androgen administration on soluble transferrin receptor in human plasma
J. Endocrinol., July 1, 2005; 186(1): 61 - 67.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Kananen, L. Volin, K. Laitinen, H. Alfthan, T. Ruutu, and M. J. Valimaki
Prevention of Bone Loss after Allogeneic Stem Cell Transplantation by Calcium, Vitamin D, and Sex Hormone Replacement with or without Pamidronate
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3877 - 3885.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Aminorroaya, S. Kelleher, A. J Conway, L. P Ly, and D. J Handelsman
Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men
Eur. J. Endocrinol., June 1, 2005; 152(6): 881 - 886.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. K. Amory and W. J. Bremner
Oral Testosterone in Oil Plus Dutasteride in Men: A Pharmacokinetic Study
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2610 - 2617.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. Laghi, W. E. Langbein, A. Antonescu-Turcu, A. Jubran, C. Bammert, and M. J. Tobin
Respiratory and Skeletal Muscles in Hypogonadal Men with Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 598 - 605.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Jasuja, P. Ramaraj, R. P. Mac, A. B. Singh, T. W. Storer, J. Artaza, A. Miller, R. Singh, W. E. Taylor, M. L. Lee, et al.
{Delta}-4-Androstene-3,17-Dione Binds Androgen Receptor, Promotes Myogenesis in Vitro, and Increases Serum Testosterone Levels, Fat-Free Mass, and Muscle Strength in Hypogonadal Men
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 855 - 863.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers
Endocrine Control of Body Composition in Infancy, Childhood, and Puberty
Endocr. Rev., February 1, 2005; 26(1): 114 - 146.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
S. T. Page, K. L. Herbst, J. K. Amory, A. D. Coviello, B. D. Anawalt, A. M. Matsumoto, and W. J. Bremner
Testosterone Administration Suppresses Adiponectin Levels in Men
J Androl, January 1, 2005; 26(1): 85 - 92.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Leberbauer, F. Boulme, G. Unfried, J. Huber, H. Beug, and E. W. Mullner
Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors
Blood, January 1, 2005; 105(1): 85 - 94.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Dhindsa, S. Prabhakar, M. Sethi, A. Bandyopadhyay, A. Chaudhuri, and P. Dandona
Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5462 - 5468.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. Sinha-Hikim, W. E. Taylor, N. F. Gonzalez-Cadavid, W. Zheng, and S. Bhasin
Androgen Receptor in Human Skeletal Muscle and Cultured Muscle Satellite Cells: Up-Regulation by Androgen Treatment
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5245 - 5255.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
E. Nieschlag, H.M. Behre, P. Bouchard, J.J. Corrales, T.H. Jones, G.K. Stalla, S.M. Webb, and F.C.W. Wu
Testosterone replacement therapy: current trends and future directions
Hum. Reprod. Update, September 1, 2004; 10(5): 409 - 419.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
Y. Ruhayel, K. Lundin, Y. Giwercman, C. Hallden, M. Willen, and A. Giwercman
Androgen receptor gene GGN and CAG polymorphisms among severely oligozoospermic and azoospermic Swedish men
Hum. Reprod., September 1, 2004; 19(9): 2076 - 2083.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Kelleher, A. J. Conway, and D. J. Handelsman
Blood Testosterone Threshold for Androgen Deficiency Symptoms
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3813 - 3817.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon, and C. Ohlsson
Androgens and Bone
Endocr. Rev., June 1, 2004; 25(3): 389 - 425.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Wang, G. Cunningham, A. Dobs, A. Iranmanesh, A. M. Matsumoto, P. J. Snyder, T. Weber, N. Berman, L. Hull, and R. S. Swerdloff
Long-Term Testosterone Gel (AndroGel) Treatment Maintains Beneficial Effects on Sexual Function and Mood, Lean and Fat Mass, and Bone Mineral Density in Hypogonadal Men
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2085 - 2098.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
E. T. Schroeder, L. Zheng, K. E. Yarasheski, D. Qian, Y. Stewart, C. Flores, C. Martinez, M. Terk, and F. R. Sattler
Treatment with oxandrolone and the durability of effects in older men
J Appl Physiol, March 1, 2004; 96(3): 1055 - 1062.
[Abstract] [Full Text] [PDF]

Home page
 Am J Sports MedHome page
N. A. Evans
Current Concepts in Anabolic-Androgenic Steroids
Am. J. Sports Med., March 1, 2004; 32(2): 534 - 542.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. K. Amory, N. B. Watts, K. A. Easley, P. R. Sutton, B. D. Anawalt, A. M. Matsumoto, W. J. Bremner, and J. L. Tenover
Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 503 - 510.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. J. Woodhouse, N. Gupta, M. Bhasin, A. B. Singh, R. Ross, J. Phillips, and S. Bhasin
Dose-Dependent Effects of Testosterone on Regional Adipose Tissue Distribution in Healthy Young Men
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 718 - 726.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. L. Rhoden and A. Morgentaler
Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring
N. Engl. J. Med., January 29, 2004; 350(5): 482 - 492.
[Full Text] [PDF]

Home page
 J. Exp. Biol.Home page
P. Koldkjaer, T. G. Pottinger, S. F. Perry, and A. R. Cossins
Seasonality of the red blood cell stress response in rainbow trout (Oncorhynchus mykiss)
J. Exp. Biol., January 15, 2004; 207(2): 357 - 367.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
S. Bhasin, W. E. Taylor, R. Singh, J. Artaza, I. Sinha-Hikim, R. Jasuja, H. Choi, and N. F. Gonzalez-Cadavid
The Mechanisms of Androgen Effects on Body Composition: Mesenchymal Pluripotent Cell as the Target of Androgen Action
J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2003; 58(12): M1103 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
S. Bhasin
Testosterone Supplementation for Aging-Associated Sarcopenia
J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2003; 58(11): M1002 - 1008.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Singh, J. N. Artaza, W. E. Taylor, N. F. Gonzalez-Cadavid, and S. Bhasin
Androgens Stimulate Myogenic Differentiation and Inhibit Adipogenesis in C3H 10T1/2 Pluripotent Cells through an Androgen Receptor-Mediated Pathway
Endocrinology, November 1, 2003; 144(11): 5081 - 5088.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
J. K. Amory, G. K. E. Scriba, D. W. Amory, and W. J. Bremner
Oral Testosterone-Triglyceride Conjugate in Rabbits: Single-Dose Pharmacokinetics and Comparison With Oral Testosterone Undecanoate
J Androl, September 1, 2003; 24(5): 716 - 720.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
Z.'e. Hochberg, K. Pacak, and G. P. Chrousos
Endocrine Withdrawal Syndromes
Endocr. Rev., August 1, 2003; 24(4): 523 - 538.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Svartberg, R. Jorde, J. Sundsfjord, K. H. Bonaa, and E. Barrett-Connor
Seasonal Variation of Testosterone and Waist to Hip Ratio in Men: The Tromso Study
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3099 - 3104.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. A. L. Crawford, P. Y. Liu, M. T. Kean, J. F. Bleasel, and D. J. Handelsman
Randomized Placebo-Controlled Trial of Androgen Effects on Muscle and Bone in Men Requiring Long-Term Systemic Glucocorticoid Treatment
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3167 - 3176.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
I. Sinha-Hikim, S. M. Roth, M. I. Lee, and S. Bhasin
Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men
Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E197 - E205.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. A. Anderson, A. M. Wallace, N. Sattar, N. Kumar, and K. Sundaram
Evidence for Tissue Selectivity of the Synthetic Androgen 7{alpha}-Methyl-19-Nortestosterone in Hypogonadal Men
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2784 - 2793.
[Abstract] [Full Text] [PDF]